Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion Pharmaceuticals names David Brennan as interim CEO
Brennan is the former Chief Executive Officer and Executive Director of AstraZeneca and has been a member of the Alexion Board of Directors since July 2014. Brennan succeeds
Brennan is the former Chief Executive Officer and Executive Director of AstraZeneca and has been a member of the Alexion Board of Directors since July 2014. Brennan succeeds
The move follows the Investigational New Drug application (IND) clearance from the US Food & Drug Administration (FDA) and the approval of the Clinical Trial Application (CTA) in
LpxC has been recognised as an attractive antibacterial target for more than the past 15 years; however, a lack of suitable chemical starting points has hampered its progress.
Preliminary analysis of the data indicates that both plecanatide 3 mg and 6 mg doses met the study’s primary endpoint and showed statistical significance in the percentage of
This is the Company's third orphan drug designation request granted by the FDA. ALS is a progressive neurodegenerative motor neuron disease that affects nerve cells in the brain
The data submitted in the NDA support the use of the regimen for 12 weeks in DAA-experienced patients with genotype 1 to 6 HCV infection without cirrhosis or
The European Medicines Agency (EMA) approved XYDALBA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. XYDALBA can be administered as either one
Specific financial terms of the agreement have not been disclosed and are not material to Endo. Endo will not have any future royalty or milestone payments to BDSI
The business includes Omega Pharma Belgium, Etixx and Biover, situated in Nazareth, Venecoweg 26 (Belgium). As part of the restructuring plan, Perrigo has agreed to end EuroGenerics’s distribution agreement for
Aclaris has initiated dosing of patients in this pharmacokinetic/pharmacodynamic (PK/PD) trial. The trial is being conducted in 12 healthy volunteers to evaluate the safety, bioavailability, and pharmacodynamics of